GTC Biotherapeutics (fka GTCB)

[biopearl]

Dew, Even with current infusion (speculated to be 6 to 8 million) for Q 4 from as yet unknown American partner, with current cash to last to Mid 2008 and little to come from European Atryn sales for HD, can you get at some estimate (unless there is a surprise) and sense of the risk of just running out of money? Dr. Cox says he does not plan to return to the markets for cash. Clearly some pharma (or DoD?) will have to ride to the rescue. There is so much great stuff going on at GTCB but not too much income generation. I would like to pick up some more shares at this price but we seem pretty close to the cliff of empty coffers. How about a little optomistic reassurance from the professor. Thanks, bp